Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3
Fasching, P.A., Esteva, F.J., Pivot, X., Nusch, A., Beck, J.T., Chan, A., Pieris-Gunatilaka, A., Wang, Y., Lanoue, B., Chandiwana, D., Neven, P.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)
Harbeck, N., Villanueva, R., Franke, F., Babu, G., Wheatley-Price, P., Im, Y.-H., Altundag, K., Lanoue, B., Alam, J., Chandiwana, D., Colleoni, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3
Jerusalem, G., Fasching, P.A., Martín, M., Pivot, X., Petrakova, K., Bianchi, G.V., Nusch, A., Sonke, G.S., De La Cruz Merino, L., Vagnon, E., Alam, J., Kong, O., Chandiwana, D., De Laurentiis, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Everolimus Plus Exemestane Compared to Exemestane and Fulvestrant for the Treatment of ER+ HER2- Metastastic Breast Cancer in the United Kingdom – A Societal Perspective
Polanyi, Z, Dale, P, Taylor, M, Lewis, L, Glanville, J, Vieira, J, Chandiwana, D
Published in Value in health (01.11.2014)
Published in Value in health (01.11.2014)
Get full text
Journal Article
A Cost Effectiveness Analysis of Everolimus Plus Exemestane Compared to Chemotherapy Agents for the Treatment of ER+ HER2- Metastastic Breast Cancer in the United Kingdom
Polanyi, Z, Dale, P, Taylor, M, Lewis, L, Glanville, J, Vieira, J, Chandiwana, D
Published in Value in health (01.11.2014)
Published in Value in health (01.11.2014)
Get full text
Journal Article
An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer
Chandiwana, D, Vieira, J, Granville, J, McCool, R, Fleetwood, K
Published in Value in health (01.11.2013)
Published in Value in health (01.11.2013)
Get full text
Journal Article
Elicitation of health state utilities in neuroendocrine tumours
Swinburn, P, Wang, J, Chandiwana, D, Mansoor, W, Lloyd, A
Published in Journal of medical economics (01.08.2012)
Published in Journal of medical economics (01.08.2012)
Get more information
Journal Article
PCN98 Health Outcome Gains and Costs Offset Associated With Everolimus for the Treatment of Hormone-Receptor–Positive (HR+) HER2-Negative (HER2–) Advanced Breast Cancer (ABC)
Taylor, M, Lewis, L, Vieira, J, Ricci, J.F, Chandiwana, D, Saletan, S, Sahmoud, T
Published in Value in health (01.11.2012)
Published in Value in health (01.11.2012)
Get full text
Journal Article
PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK
Botteman, M.F, Carter, J.A, Fishman, P, Chandiwana, D, Bains, M, Snedecor, S.J
Published in Value in health (01.11.2012)
Published in Value in health (01.11.2012)
Get full text
Journal Article
Cost-effectiveness of first-line ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
Cameron, D.A., Sharma, V.K., Biswas, C., Clarke, C., Chandiwana, D., Pathak, P.
Published in European journal of cancer (1990) (01.11.2022)
Published in European journal of cancer (1990) (01.11.2022)
Get full text
Journal Article
EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC)
Cameron, D, Sharma, V, Biswas, C, Clarke, C, Chandiwana, D, Pathak, P
Published in Value in health (01.12.2022)
Published in Value in health (01.12.2022)
Get full text
Journal Article
PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
Stellato, D., Thabane, M., Chandiwana, D., Lanoue, B., Delea, T.E.
Published in Value in health (01.05.2020)
Published in Value in health (01.05.2020)
Get full text
Journal Article
PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
Stellato, D., Thabane, M., Chandiwana, D., Lanoue, B., Delea, T.E.
Published in Value in health (01.05.2020)
Published in Value in health (01.05.2020)
Get full text
Journal Article
332P Treatment-emergent (TE) neutropenia and related hospitalizations and medication discontinuations in patients (pts) with metastatic breast cancer (MBC) treated with palbociclib (PAL) or ribociclib (RIB): A real-world analysis
Schwartzberg, L., Kanakamedala, H., Thuerigen, A., Chandiwana, D., Yu, C-L., Balu, S., Turner, S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article